INO Financial Facts
General and administrative: 5.76MLicense fee and milestone revenue: 2.33M
See Full Income Statement
Goodwill: 10.51M
Accumulated deficit: -408.6M
See Full Balance Sheet
Inovio Pharma (INO) Earnings
|
Expand Research on INO
| Next EPS Date | 5/8/24 | EPS Growth Rate | -625.0% |
|---|---|---|---|
| Average EPS % Beat Rate | +55.3% | Revenue Growth Rate | +490.9% |
| Average % Move 1-Wk after EPS | -0.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/8/17 | Q217 | $0.00 | -$0.19 | +$0.19 | $20.4M | $16.29M | = |  | | Details | |
| 11/8/17 |  |
Q317 | -$0.39 | -$0.25 | -$0.14 | $2.6M | $9.36M | = | | | Details |
| 3/14/18 | |
Q417 | -$0.24 | -$0.30 | +$0.06 | $8.8M | $7.53M | = | | | Details |
| 5/11/15 | Q115 | -$0.17 | -$0.11 | -$0.06 | $5.2M | $7.04M | N/A | | | Details | |
| 3/14/16 | Q415 | -$0.25 | -$0.20 | -$0.05 | $5.94M | $6.96M | N/A | | | Details | |
| 3/15/17 | Q416 | -$0.35 | -$0.30 | -$0.05 | $8.5M | $5.95M | = | | | Details | |
5/10/01  |
Q117 | N/A | -$0.31 | N/A | N/A | $5.83M | = | N/A | N/A | ||
| 8/8/19 | |
Q219 | -$0.30 | -$0.27 | -$0.03 | $135.67K | $5.66M | N/A | | | Details |
